We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal
Read MoreHide Full Article
Entasis announced positive top-line data from the phase III ATTACK study evaluating its investigational intravenous (IV) drug, sulbactam-durlobactam (“SUL-DUR”), in patients having infections caused by Acinetobacter baumannii.
The ATTACK study evaluated the efficacy and safety of SUL-DUR in comparison with colistin in carbapenem-resistant Acinetobacter (“CRAB”) patients in 17 countries. The study met the primary endpoint of 28-day all-cause mortality in CRAB patients, demonstrating statistical non-inferiority over colistin.
Entasis also reported that participants administered SUL-DUR exhibited a favorable safety profile over colistin including a statistically significant reduction in nephrotoxicity.
Shares gained 4.2% on Oct 19. In fact, the stock has rallied 31.2% so far this year against the industry’s 16.6% decline.
Image Source: Zacks Investment Research
Please note that SUL-DUR is a combination of sulbactam and durlobactam, an IV β-lactam antibiotic and a novel broad-spectrum IV β-lactamase inhibitor, respectively, developed to treat infections caused by Acinetobacter baumannii, including CRAB.
The company has also partnered with Zai Lab (ZLAB - Free Report) to develop and commercialize the drug in Australia along with multiple Asian countries including mainland China as well as Japan.
We inform investors that Acinetobacter is a gram-negative pathogen that infects critically ill patients. While the pathogen causes severe pneumonia and bloodstream infections, it can also infect the skin and urinary tract. The infections caused by Acinetobacter also develop multidrug resistance.
Currently, there are limited treatment options for people suffering from Acinetobacter. Per company estimates, more than 300,000 hospital-treated CRAB infections exist annually across the United States, Europe, the Middle East and China. Potential approval and successful commercialization of the drug would boost revenue prospects for the company in the long term. It anticipates the submission of a new drug application with the FDA in mid-2022.
Entasis currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the same sector are Enanta Pharmaceuticals (ENTA - Free Report) and Xencor (XNCR - Free Report) . While Xencor currently sports a Zacks Rank #1 (Strong Buy), Enata carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Enata’s earnings per share estimates for 2021 have narrowed from $4.32 to $3.88 in the past 60 days. The same for 2022 has narrowed from $6.24 to $4.73 over the same period. The stock has surged 65.8% in the year so far.
Xencor’s earnings per share estimates for 2021 have narrowed from $0.75 to $0.33 in the past 60 days. The same for 2022 has narrowed from $3.14 to $2.92 over the same period.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal
Entasis announced positive top-line data from the phase III ATTACK study evaluating its investigational intravenous (IV) drug, sulbactam-durlobactam (“SUL-DUR”), in patients having infections caused by Acinetobacter baumannii.
The ATTACK study evaluated the efficacy and safety of SUL-DUR in comparison with colistin in carbapenem-resistant Acinetobacter (“CRAB”) patients in 17 countries. The study met the primary endpoint of 28-day all-cause mortality in CRAB patients, demonstrating statistical non-inferiority over colistin.
Entasis also reported that participants administered SUL-DUR exhibited a favorable safety profile over colistin including a statistically significant reduction in nephrotoxicity.
Shares gained 4.2% on Oct 19. In fact, the stock has rallied 31.2% so far this year against the industry’s 16.6% decline.
Please note that SUL-DUR is a combination of sulbactam and durlobactam, an IV β-lactam antibiotic and a novel broad-spectrum IV β-lactamase inhibitor, respectively, developed to treat infections caused by Acinetobacter baumannii, including CRAB.
The company has also partnered with Zai Lab (ZLAB - Free Report) to develop and commercialize the drug in Australia along with multiple Asian countries including mainland China as well as Japan.
We inform investors that Acinetobacter is a gram-negative pathogen that infects critically ill patients. While the pathogen causes severe pneumonia and bloodstream infections, it can also infect the skin and urinary tract. The infections caused by Acinetobacter also develop multidrug resistance.
Currently, there are limited treatment options for people suffering from Acinetobacter. Per company estimates, more than 300,000 hospital-treated CRAB infections exist annually across the United States, Europe, the Middle East and China. Potential approval and successful commercialization of the drug would boost revenue prospects for the company in the long term. It anticipates the submission of a new drug application with the FDA in mid-2022.
Entasis Therapeutics Holdings Inc. Price
Entasis Therapeutics Holdings Inc. price | Entasis Therapeutics Holdings Inc. Quote
Zacks Rank & Stocks to Consider
Entasis currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the same sector are Enanta Pharmaceuticals (ENTA - Free Report) and Xencor (XNCR - Free Report) . While Xencor currently sports a Zacks Rank #1 (Strong Buy), Enata carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Enata’s earnings per share estimates for 2021 have narrowed from $4.32 to $3.88 in the past 60 days. The same for 2022 has narrowed from $6.24 to $4.73 over the same period. The stock has surged 65.8% in the year so far.
Xencor’s earnings per share estimates for 2021 have narrowed from $0.75 to $0.33 in the past 60 days. The same for 2022 has narrowed from $3.14 to $2.92 over the same period.